A Lactobacillus Combination Ameliorates Lung Inflammation in an Elastase/LPS—induced Mouse Model of Chronic Obstructive Pulmonary Disease
Eine Lactobacillus-Kombination vermindert Lungenentzündung in einem Elastase/LPS-induzierten Mausmodell der COPD
Probiotics and Antimicrobial Proteins · 2025-10 · 17 (5) · 3416-3428
DOI: 10.1007/s12602-024-10300-9 ↗Auf einen Blick
In einem COPD-Mausmodell senkte eine Kombination aus Limosilactobacillus reuteri GMNL-89 und Lacticaseibacillus paracasei GMNL-133 Lungenemphysem und Entzündungsmarker.
Fragestellung
Verringert eine LAB-Kombination aus L. reuteri GMNL-89 und L. paracasei GMNL-133 Lungenentzündung und Emphysem im COPD-Mausmodell?
Methode
COPD-Mausmodell mit intranasaler Elastase- und LPS-Stimulation über 4 Wochen, danach 2 Wochen orale LAB-Gabe. Untersuchung von Lungenentzündung, Emphysem und Mikrobiomveränderungen.
Ergebnisse
Die LAB-Kombination verringerte Lungenemphysem und die Zytokine IL-1β, IL-6 und TNF-α im Lungengewebe. Zudem wurden Veränderungen des Darm- und Lungenmikrobioms sowie mehr Essigsäure und Propionsäure beschrieben.
Schlussfolgerung der Autor:innen
Die Kombination aus L. reuteri GMNL-89 und L. paracasei GMNL-133 zeigte günstige Effekte auf Emphysem und Entzündung bei experimenteller COPD bei Mäusen und könnte eine künftige adjuvante Strategie sein.
Kernaussagen
- Weniger Lungenemphysem unter LAB-Behandlung
- IL-1β, IL-6 und TNF-α im Lungengewebe reduziert
- Veränderungen von Darm- und Lungenmikrobiota berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, online erschienen am 12.06.2024. Verfasst von Huan-Ting Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 88, Sec. 1, Fengxing Rd., Tanzi Dist., Taichung…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Lactobacillaceae. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: E-Da Hospital.
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is the world's leading lung disease and lacks effective and specific clinical strategies. Probiotics are increasingly used to support the improvement of the course of inflammatory diseases. In this study, we evaluated the potential of a lactic acid bacteria (LAB) combination containing Limosilactobacillus reuteri GMNL-89 and Lacticaseibacillus paracasei GMNL-133 to decrease lung inflammation and emphysema in a COPD mouse model. This model was induced by intranasal stimulation with elastase and LPS for 4 weeks, followed by 2 weeks of oral LAB administration. The results showed that the LAB combination decreased lung emphysema and reduced inflammatory cytokines (IL-1β, IL-6, TNF-α) in the lung tissue of COPD mice. Microbiome analysis revealed that Bifidobacterium and Akkermansia muciniphila , reduced in the gut of COPD mice, could be restored after LAB treatment. Microbial α-diversity in the lungs decreased in COPD mice but was reversed after LAB administration, which also increased the relative abundance of Candidatus arthromitus in the gut and decreased Burkholderia in the lungs. Furthermore, LAB-treated COPD mice exhibited increased levels of short-chain fatty acids, specifically acetic acid and propionic acid, in the cecum. Additionally, pulmonary emphysema and inflammation negatively correlated with C. arthromitus and Adlercreutzia levels. In conclusion, the combination of L. reuteri GMNL-89 and L. paracasei GMNL-133 demonstrates beneficial effects on pulmonary emphysema and inflammation in experimental COPD mice, correlating with changes in gut and lung microbiota, and providing a potential strategy for future adjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 88, Sec. 1, Fengxing Rd., Tanzi Dist., Taichung City, 427003, Taiwan.
- Research and Development Department, GenMont Biotech Incorporation, No.8, Nanke 7th Rd., Shanhua Dist., Tainan City, 741014, Taiwan.
- Division of Respiratory and Chest Medicine, Department of Internal Medicine, E-Da Cancer Hospital, No. 1, Yida Rd, Yanchao Dist, Kaohsiung City, 824005, Taiwan.
- Aging and Disease Prevention Research Center, Fooyin University, No. 151, Jinxue Rd., Daliao Dist., Kaohsiung City, 831301, Taiwan.
- Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, No. 135, Nanhsiao Street, Changhua County, 500209, Taiwan. 156283@cch.org.tw.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, No. 145, Xingda Rd., South Dist., Taichung City, 402202, Taiwan. 156283@cch.org.tw.
Förderung
- E-Da Hospital
Zitieren
APA
Shen, H. T., Fang, Y. T., Tsai, W. H., Chou, C. H., Huang, M. S., Yeh, Y. T., Wu, J. T., Huang, C. H., Wang, B. Y., & Chang, W. W. (2025). A Lactobacillus Combination Ameliorates Lung Inflammation in an Elastase/LPS—induced Mouse Model of Chronic Obstructive Pulmonary Disease. Probiotics and Antimicrobial Proteins, 17(5), 3416-3428. https://doi.org/10.1007/s12602-024-10300-9
Vancouver
Shen HT, Fang YT, Tsai WH, Chou CH, Huang MS, Yeh YT, et al. A Lactobacillus Combination Ameliorates Lung Inflammation in an Elastase/LPS—induced Mouse Model of Chronic Obstructive Pulmonary Disease. Probiotics and Antimicrobial Proteins. 2025;17(5):3416-3428. doi:10.1007/s12602-024-10300-9
BibTeX
@article{Shen2025,
author = {Shen, Huan-Ting and Fang, Yi-Ting and Tsai, Wan-Hua and Chou, Chia-Hsuan and Huang, Ming-Shyan and Yeh, Yao-Tsung and Wu, Jiun-Ting and Huang, Cheng-Hsieh and Wang, Bing-Yen and Chang, Wen-Wei},
title = {A Lactobacillus Combination Ameliorates Lung Inflammation in an Elastase/LPS—induced Mouse Model of Chronic Obstructive Pulmonary Disease},
journal = {Probiotics and Antimicrobial Proteins},
year = {2025},
volume = {17},
number = {5},
pages = {3416--3428},
doi = {10.1007/s12602-024-10300-9}
}
EUVIMED